Bruker Corporation $BRKR Shares Sold by Vanguard Group Inc.

Vanguard Group Inc. lessened its position in shares of Bruker Corporation (NASDAQ:BRKR) by 1.4% in the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 10,259,824 shares of the medical research company’s stock after selling 144,437 shares during the period. Vanguard Group Inc. owned about 0.07% of Bruker worth $483,340,000 as of its most recent SEC filing.

Other large investors also recently modified their holdings of the company. Royal Bank of Canada raised its holdings in shares of Bruker by 8.3% in the 1st quarter. Royal Bank of Canada now owns 123,336 shares of the medical research company’s stock valued at $5,148,000 after purchasing an additional 9,501 shares in the last quarter. Jacobs Levy Equity Management Inc. acquired a new position in shares of Bruker during the first quarter worth $262,000. Goldman Sachs Group Inc. grew its stake in shares of Bruker by 107.3% during the first quarter. Goldman Sachs Group Inc. now owns 1,465,319 shares of the medical research company’s stock worth $61,162,000 after purchasing an additional 758,301 shares in the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC increased its holdings in Bruker by 2.6% in the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 366,204 shares of the medical research company’s stock valued at $15,285,000 after buying an additional 9,235 shares during the last quarter. Finally, Focus Partners Wealth increased its holdings in Bruker by 115.0% in the first quarter. Focus Partners Wealth now owns 11,232 shares of the medical research company’s stock valued at $469,000 after buying an additional 6,008 shares during the last quarter. 79.52% of the stock is owned by hedge funds and other institutional investors.

Bruker Stock Up 4.5%

BRKR opened at $38.01 on Wednesday. Bruker Corporation has a one year low of $28.53 and a one year high of $56.22. The company has a debt-to-equity ratio of 0.75, a quick ratio of 0.87 and a current ratio of 1.73. The stock has a market capitalization of $5.79 billion, a P/E ratio of -253.40, a price-to-earnings-growth ratio of 2.18 and a beta of 1.12. The business’s 50-day simple moving average is $37.13 and its 200-day simple moving average is $41.99.

Bruker (NASDAQ:BRKR) last released its quarterly earnings results on Wednesday, May 6th. The medical research company reported $0.31 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.23 by $0.08. The firm had revenue of $823.40 million for the quarter, compared to the consensus estimate of $796.11 million. Bruker had a positive return on equity of 13.56% and a negative net margin of 0.25%.Bruker has set its FY 2026 guidance at 2.100-2.150 EPS. Analysts anticipate that Bruker Corporation will post 2.12 EPS for the current year.

Bruker Announces Dividend

The firm also recently announced a quarterly dividend, which was paid on Tuesday, April 7th. Stockholders of record on Monday, March 23rd were given a dividend of $0.05 per share. The ex-dividend date was Monday, March 23rd. This represents a $0.20 dividend on an annualized basis and a dividend yield of 0.5%. Bruker’s dividend payout ratio (DPR) is -133.33%.

Analyst Ratings Changes

A number of brokerages have issued reports on BRKR. Guggenheim decreased their price target on Bruker from $58.00 to $50.00 and set a “buy” rating for the company in a report on Monday, March 30th. The Goldman Sachs Group dropped their price objective on Bruker from $40.00 to $35.00 and set a “sell” rating on the stock in a report on Friday, February 13th. Barclays cut their target price on Bruker from $50.00 to $45.00 and set an “overweight” rating on the stock in a research report on Tuesday, April 14th. TD Cowen raised Bruker to a “hold” rating in a report on Monday, April 13th. Finally, Weiss Ratings upgraded shares of Bruker from a “sell (d)” rating to a “sell (d+)” rating in a research report on Friday, April 24th. One investment analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating, five have issued a Hold rating and two have issued a Sell rating to the company. According to data from MarketBeat, the company has a consensus rating of “Hold” and a consensus price target of $49.38.

Insider Activity at Bruker

In related news, VP Mark Munch sold 2,000 shares of the company’s stock in a transaction on Wednesday, April 15th. The shares were sold at an average price of $39.90, for a total value of $79,800.00. Following the completion of the sale, the vice president owned 128,443 shares in the company, valued at $5,124,875.70. This represents a 1.53% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. 27.20% of the stock is owned by insiders.

Bruker Company Profile

Bruker Corporation, founded in 1960 by physicist Günther Laukien and headquartered in Billerica, Massachusetts, is a leading developer and manufacturer of high-performance scientific instruments and analytical solutions. The company designs systems that enable molecular and materials research across academic, governmental, and industrial laboratories.

Bruker’s product portfolio encompasses nuclear magnetic resonance (NMR) spectrometers for molecular structure and dynamics studies, mass spectrometry platforms for proteomics and metabolomics, X-ray diffraction and scattering instruments for crystallography and materials characterization, atomic force and scanning probe microscopes for nanoscale surface analysis, as well as preclinical imaging systems such as micro-CT and MRI scanners.

In addition to hardware, Bruker provides software suites, applications support, training services, and long-term maintenance agreements to ensure optimal instrument performance.